Argenx Se (ARGX) Common Equity (2015 - 2025)
Argenx Se's (ARGX) quarterly Common Equity came in at $7.3 billion in Q4 2025, up 33.19% YoY from $5.5 billion in Q4 2024, and down 99.88% on a QoQ basis from $6095.8 billion in Q2 2025.
Argenx Se (ARGX) Common Equity (2015 - 2025) Analysis & Trends
Argenx Se (ARGX) has 11 years of Common Equity data on file, last reported at $7.3 billion in Q4 2025.
- Quarterly Common Equity rose 33.19% year-over-year to $7.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 billion (up 33.19% YoY) and the FY2025 annual result came in at $7.3 billion, up 33.19% from the prior year.
- Common Equity retreated to $7.3 billion in Q4 2025, from $6095.8 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $6095.8 billion in Q2 2025 to a low of $2.5 billion in Q4 2021.
- A 5-year average of $613.1 billion and a median of $3.5 billion in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity retreated 3.78% — and 2025, when it jumped 142917.33%.
- Tracing ARGX's Common Equity over 5 years: stood at $2.5 billion in 2021, then gained by 11.03% to $2.8 billion in 2022, then jumped by 45.63% to $4.1 billion in 2023, then surged by 34.19% to $5.5 billion in 2024, then soared by 33.19% to $7.3 billion in 2025.
- The last three Common Equity figures came in at $7.3 billion (Q4 2025), $6095.8 billion (Q2 2025), and $5.5 billion (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.32 Bn |
| Jun 30, 2025 | 6,095.75 Bn |
| Dec 31, 2024 | 5.50 Bn |
| Jun 30, 2024 | 4.26 Bn |
| Dec 31, 2023 | 4.10 Bn |
| Jun 30, 2023 | 2.86 Bn |
| Dec 31, 2022 | 2.81 Bn |
| Jun 30, 2022 | 2.97 Bn |
| Dec 31, 2021 | 2.53 Bn |
| Jun 30, 2021 | 2.95 Bn |
| Dec 31, 2020 | 1.63 Bn |
| Jun 30, 2020 | 1.81 Bn |
| Dec 31, 2019 | 1.16 Bn |
| Jun 30, 2019 | 930.56 Mn |
| Dec 31, 2018 | 614.52 Mn |
| Jun 30, 2018 | 515.77 Mn |
| Dec 31, 2017 | 403.31 Mn |
| Jun 30, 2017 | 165.21 Mn |
| Dec 31, 2016 | 68.43 Mn |
| Dec 31, 2015 | 40.86 Mn |